mynth
05/2025MajorityLBO

IK Partners takes majority stake in Biobank

FRANCE Life Sciences / Medical Devices / Implants & Prosthetics EV €50–150M

Context

This transaction structurally constitutes a tertiary leveraged buyout, marking a significant reorganization of the target's capital structure. The incoming pan-European financial sponsor successfully preempted a highly competitive auction process orchestrated by a specialized investment bank, decisively securing a majority controlling stake. Crucially, the operation features substantial reinvestments from both historical private equity partners and the entire executive management team, ensuring total long-term strategic alignment. The capital structure is completed by a bespoke unitranche debt facility currently under final negotiation. The primary strategic rationale underpinning this renewed financial partnership is to massively accelerate the company's international rollout. The explicit roadmap mandates robust external growth through targeted acquisitions and the establishment of new distributor partnerships across specific neighboring European countries, aiming to swiftly replicate its domestic dominance on a continental scale.

Biobank, which reported an EBITDA margin of [members only] in 2023, is valued in this transaction at an EV/EBITDA multiple of 10x–18x, standing directly in line with the average observed in the Healthcare & Pharma sector (14.5x in 2025).

-> Deep-dive in Healthcare & Pharma market trends

Target

Biobank is a specialized medtech company and the undisputed domestic market leader in providing bone allografts to orthopedic surgeons. These critical grafts are sustainably sourced from living donors during specific surgical procedures. The company boasts a highly resilient and exceptionally secure operational risk profile. Over recent years, the firm has successfully transformed from a localized entity into a robust international player, establishing a strong regulatory, clinical, and marketing foundation. Its superior allograft technology is steadily replacing traditional alternative techniques across the medical field. Following a successful historical acquisition of its Swiss distributor, the enterprise is strategically positioned to leverage its advanced technological edge to continuously expand and ultimately capture the premier leadership position across the entire European orthopedic grafting market.

Ent. Value

€50–150M

Equity Value

[members only]

Multiples

EV / Revenue

2x–6x

EV / EBITDA

10x–18x

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2023
€10–30M
€5–25M
[members only]
2022
€10–30M
€5–25M
[members only]

Other operations with IK Partners

Other operations with IK Partners
DateAcquirerTargetCountrySector
04/2026IK PARTNERSSELATEKSWEDENElectrical
03/2026IK PARTNERSDOMEK GROUPNETHERLANDSBrokerage
12/2025IK PARTNERSRHETORESFRANCEWealth & Asset Management
12/2025IK PARTNERSASCORAFRANCEBrokerage
11/2025IK PARTNERSENDRIX (EX SFC)FRANCEAccounting & Audit
08/2025IK PARTNERSFRANCKS KYLINDUSTRISWEDENHVAC (Heating/AC)
05/2025IK PARTNERSDATAPART FACTORINGGERMANYFactoring
05/2025IK PARTNERSKESTREL CAPITALIRELANDWealth & Asset Management
05/2025IK PARTNERSLOHOFF PENSION SERVICESGERMANYERP, HR & Finance
04/2025IK PARTNERSSTERIMEDFRANCEMedical Consumables

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
07/2025PATRICIA INDUSTRIESNOVA BIOMEDICALUNITED STATESDiagnostic Equipment
07/2025BC PARTNERSBIOGARANFRANCEPharma & Biotech
05/2025OTTOBOCKMATTON ORTHOMEDIBELGIUMImplants & Prosthetics
04/2025CINVENNUTRISENSFRANCENutrition & Dietary Supplements
04/2025INSTITUT MERIEUX / ARCHIMEDCEVA SANTE ANIMALEFRANCEAnimal Health
04/2025PATIENT SQUARE CAPITALPATTERSON COMPANIESUNITED STATESMedical Consumables
04/2025IK PARTNERSSTERIMEDFRANCEMedical Consumables
04/2025KNOP INVESTMENTSAVANCE CARE GROUPNETHERLANDSMedical Devices
04/2025NORGINETHERAVIAFRANCEGenerics / Labs
03/2025ZYDUSAMPLITUDE SURGICALFRANCEImplants & Prosthetics

REFERENCES

Valuation range: EV €50–150M

Revenue range: €10–30M

EBITDA range: €5–25M

EV/Revenue range: 2x - 6x

EV/EBITDA range: 10x - 18x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Biobank by IK Partners are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Acquirer: ik partners

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in Biobank, a French company specialised in Medical Devices, by IK Partners in 2025, structured as a leveraged buyout (LBO).

How was the acquisition of Biobank by IK Partners valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €50–150M band, its EV/EBITDA multiple within the 10x - 18x range, and its EV/revenue multiple within the 2x - 6x range. Exact figures are available to members.

What were Biobank’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Biobank generated annual revenue estimated in the €10–30M range and EBITDA in the €5–25M bracket (FY 2023). Detailed financial figures are available to members.

How does the valuation of Biobank compare to benchmarks in the Healthcare & Pharma sector?

With an estimated multiple range of 10x - 18x, the transaction stands directly in line with historical averages for the Healthcare & Pharma sector (14.5x in 2025).

What sources support the information on this transaction?

Data on this transaction was compiled from the official corporate announcement published by the parties, combined with independent reporting from specialized financial and M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.